Increased nigral iron content in postmortem parkinsonian brain - PubMed (original) (raw)

Increased nigral iron content in postmortem parkinsonian brain

D T Dexter et al. Lancet. 1987.

No abstract available

PubMed Disclaimer

Similar articles

• The history of the research of iron in parkinsonian substantia nigra.
  Friedman A, Galazka-Friedman J. Friedman A, et al. J Neural Transm (Vienna). 2012 Dec;119(12):1507-10. doi: 10.1007/s00702-012-0894-8. Epub 2012 Sep 2. J Neural Transm (Vienna). 2012. PMID: 22941506 Free PMC article. Review.
• Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
  Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH. Mann VM, et al. Ann Neurol. 1994 Dec;36(6):876-81. doi: 10.1002/ana.410360612. Ann Neurol. 1994. PMID: 7998774
• Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects.
  Javoy-Agid F, Ruberg M, Taquet H, Studler JM, Garbarg M, Llorens C, Schwartz JC, Grouselle D, Lloyd KG, Raisman R, Agid Y. Javoy-Agid F, et al. Adv Neurol. 1982;35:151-63. Adv Neurol. 1982. PMID: 6128885 No abstract available.
• [Mossbauer spectroscopy of iron in substantia nigra in Parkinson disease and controls].
  Friedman A, Bauminger ER, Gałazka-Friedman J, Barcikowska M, Suwalski J, Hechel D, Dymecki J, Nowik I. Friedman A, et al. Neurol Neurochir Pol. 1994;28(1 Suppl 1):145-55. Neurol Neurochir Pol. 1994. PMID: 8065540 Polish.
• What process causes nigral cell death in Parkinson's disease?
  Jenner P. Jenner P. Neurol Clin. 1992 May;10(2):387-403. Neurol Clin. 1992. PMID: 1584181 Review.

Cited by

• Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.
  Wang Y, Wu S, Li Q, Lang W, Li W, Jiang X, Wan Z, Chen J, Wang H. Wang Y, et al. Front Pharmacol. 2022 Sep 12;13:977521. doi: 10.3389/fphar.2022.977521. eCollection 2022. Front Pharmacol. 2022. PMID: 36172194 Free PMC article. Review.
• The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
  Nagatsu T, Nakashima A, Watanabe H, Ito S, Wakamatsu K, Zucca FA, Zecca L, Youdim M, Wulf M, Riederer P, Dijkstra JM. Nagatsu T, et al. J Neural Transm (Vienna). 2023 May;130(5):611-625. doi: 10.1007/s00702-023-02617-6. Epub 2023 Mar 20. J Neural Transm (Vienna). 2023. PMID: 36939908 Free PMC article. Review.
• The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders.
  Urrutia PJ, Mena NP, Núñez MT. Urrutia PJ, et al. Front Pharmacol. 2014 Mar 10;5:38. doi: 10.3389/fphar.2014.00038. eCollection 2014. Front Pharmacol. 2014. PMID: 24653700 Free PMC article. Review.
• Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
  Chen Q, Chen Y, Zhang Y, Wang F, Yu H, Zhang C, Jiang Z, Luo W. Chen Q, et al. BMC Neurosci. 2019 May 22;20(1):23. doi: 10.1186/s12868-019-0505-9. BMC Neurosci. 2019. PMID: 31117957 Free PMC article.
• Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.
  Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JI, Ritz B. Rhodes SL, et al. Neurobiol Dis. 2014 Feb;62:172-8. doi: 10.1016/j.nbd.2013.09.019. Epub 2013 Oct 8. Neurobiol Dis. 2014. PMID: 24121126 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Medical

  • MedlinePlus Health Information